Sir-Alonso and colleagues (Oct 29, p 1175) report a decrease id the frequency of clinical
malaria among Tanzanian children who had received the SPf66 malaria vaccine developed …

Nosten and colleagues' trial of SPf66 vaccine in Karen children aged 2–15 years contrasts
with two other randomised trials in areas with similar malaria epidemiology. On the the …

SPf66 malaria vaccine is a synthetic protein with aminoacid sequences derived from pre-
erythrocytic and asexual blood-stage proteins of Plasmodium falciparum. SPf66 was found …

Background Previous efficacy trials of SPf66 malaria vaccine have produced conflicting
results in different populations. We report a randomised double-blind trial of the SPf66 …

1 Nosten F, Luxemberger C, Kyle DE, et al. Randomised double-blind placebo-controlled
trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet 1996; 348: 701 …

Effective, safe antimalarial vaccines have proved elusive. The synthetic polypeptide SPf66
vaccine is based on pre-erythrocytic and asexual blood-stage proteins of Plasmodium …

Efforts to control and further reduce morbidity and mortality caused by Plasmodium
falciparum infections in all age groups will be substantially strengthened by development of …

Preclinical and clinical studies have established the safety and immunogenicity of the
chemically synthesised SPf66 malaria vaccine. The present study is a phase III randomised …

The epidemiology of severe and complicated P falciparum malaria provides a compelling
argument for vaccine development. In malaria-endemic areas, children bear the brunt of …

Malaria, especially that due to Plasmodium falciparum, is one of the most important parasitic
disease in man. It causes more than 400 million cases per year and between 1 to 3 million …